Randomized trial · people

Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with HIV and extra belly fat on ART, tesamorelin shrank deep belly fat compared with placebo, and the loss held through 52 weeks in those who kept taking it.

Kind
Randomized trial
Studied in
People
Number studied
806
Published
2010
Journal
J Clin Endocrinol Metab

What they tested

The team tested whether tesamorelin shrinks visceral fat (deep fat around the organs) in people with HIV on antiretroviral therapy (ART, HIV medicines) who carry extra belly fat.

How the study was done

A pooled analysis of two randomized, double-blind, placebo-controlled phase 3 trials in 806 people with HIV on ART, given a daily under-the-skin shot of tesamorelin 2 mg (543 people) or placebo, a dummy shot (263 people), for 26 weeks. A 26-week extension followed: some on tesamorelin were randomized again to stay on it (246) or switch to placebo (135), and those on placebo switched to tesamorelin (197).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 26 weeks, visceral fat on CT scan fell by 24 cm² with tesamorelin and rose by 2 cm² with placebo, a treatment effect of -15.4%. Fat just under the skin of the belly did not change significantly, while triglycerides dropped by 37 mg/dl versus a 6 mg/dl rise on placebo, and IGF-I rose by 108 ng/ml versus a 7 ng/ml drop. Body image and patient and physician ratings of belly shape also improved. In people who stayed on tesamorelin for 52 weeks, visceral fat was down 35 cm² (17.5%) and waist size down 3.4 cm from the start, most people tolerated the drug, and glucose measures showed no meaningful differences between groups.

What it doesn’t show

The placebo comparison lasted only 26 weeks; the 52-week results compare one group with its own starting point, not with placebo. Everyone studied had HIV and was on ART, so it does not show effects in other people.

The paper

Falutz et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010.

The compound

More studies on Tesamorelin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo